JNJ

238.9

+1.85%↑

UNH

271.02

-2.8%↓

TMO

552.32

-3.65%↓

ABT

109.1

+0.24%↑

ISRG

482.13

+1.33%↑

JNJ

238.9

+1.85%↑

UNH

271.02

-2.8%↓

TMO

552.32

-3.65%↓

ABT

109.1

+0.24%↑

ISRG

482.13

+1.33%↑

JNJ

238.9

+1.85%↑

UNH

271.02

-2.8%↓

TMO

552.32

-3.65%↓

ABT

109.1

+0.24%↑

ISRG

482.13

+1.33%↑

JNJ

238.9

+1.85%↑

UNH

271.02

-2.8%↓

TMO

552.32

-3.65%↓

ABT

109.1

+0.24%↑

ISRG

482.13

+1.33%↑

JNJ

238.9

+1.85%↑

UNH

271.02

-2.8%↓

TMO

552.32

-3.65%↓

ABT

109.1

+0.24%↑

ISRG

482.13

+1.33%↑

Начало・Списък с акции・AbCellera Biologics Inc

AbCellera Biologics Inc

Отворен

СекторЗдравеопазване

3.05 -8.13

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.04

Максимум

3.31

Ключови измерители
By Trading Economics
Приходи	-22M -57M
Продажби	-8.1M 9M
Марж на печалбата	-637.845
Служители	596
EBITDA	-1.4M -40M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+89.49% upside

Дивиденти
By Dow Jones
Следващи печалби	24.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-557M 1B
Предишно отваряне	11.18
Предишно затваряне	3.05

Настроения в новините

By Acuity

63%

37%

308 / 352 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.99 / 2.635 Подкрепа & съпротива

AbCellera Biologics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

5.02.2026 г., 00:00 ч. UTC

Горещи акции

Stocks to Watch: Crown Castle, Qualcomm, Arm, U-Haul

4.02.2026 г., 22:55 ч. UTC

Печалби

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook -- Update

4.02.2026 г., 21:44 ч. UTC

Печалби

Arm Holdings 3Q Profit Falls Despite Revenue Growth

4.02.2026 г., 21:39 ч. UTC

Печалби

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook

5.02.2026 г., 00:00 ч. UTC

Печалби

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

5.02.2026 г., 00:00 ч. UTC

Печалби

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

4.02.2026 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

4.02.2026 г., 23:45 ч. UTC

Печалби

Google to Double Spending as Earnings Beat Wall Street Expectations -- 4th Update

4.02.2026 г., 23:32 ч. UTC

Пазарно говорене

Gold Rises on Possible Dip-Buying Amid Lingering U.S.-Iran Tensions -- Market Talk

4.02.2026 г., 22:59 ч. UTC

Придобивния, сливания и поглъщания

SiTime to Buy Timing Business From Renesas Electronics For $1.5B

4.02.2026 г., 22:30 ч. UTC

Печалби

Salesforce Stock Is Battered, and Super Cheap. Hang Tight. -- Barrons.com

4.02.2026 г., 22:30 ч. UTC

Печалби

Alphabet's Cloud Is Shining as CapEx Heads Even Higher -- Barrons.com

4.02.2026 г., 22:21 ч. UTC

Печалби

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4.02.2026 г., 22:17 ч. UTC

Пазарно говорене

WiseTech Faces Risks in Both Directions From DSV's Progress -- Market Talk

4.02.2026 г., 22:15 ч. UTC

Пазарно говорене

Santos Should Lay Out Strategic Plans at Annual Result -- Market Talk

4.02.2026 г., 22:00 ч. UTC

Пазарно говорене

ESG Roundup: Market Talk

4.02.2026 г., 21:53 ч. UTC

Печалби

Google to Double Spending as Earnings Beat Wall Street Expectations -- 3rd Update

4.02.2026 г., 21:51 ч. UTC

Печалби

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

4.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

4.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Печалби

Auto & Transport Roundup: Market Talk

4.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

4.02.2026 г., 21:45 ч. UTC

Печалби

Arm Holdings Reported Record Revenue. The Stock is Falling. -- Barrons.com

4.02.2026 г., 21:44 ч. UTC

Печалби

Qualcomm Gives Weak Guidance. The CEO Blames Memory Crunch. -- Barrons.com

4.02.2026 г., 21:43 ч. UTC

Печалби

Google to Double Spending as Earnings Beat Wall Street Expectations -- 2nd Update

4.02.2026 г., 21:41 ч. UTC

Печалби

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4.02.2026 г., 21:36 ч. UTC

Пазарно говорене

Latest Canada Green Bond Raises C$2 Billion -- Market Talk

4.02.2026 г., 21:30 ч. UTC

Печалби

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4.02.2026 г., 21:30 ч. UTC

Печалби

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4.02.2026 г., 21:30 ч. UTC

Печалби

Beach Energy Interim Dividend 1 Australian Cent/Sjare

Сравнение с други в отрасъла

Ценова промяна

AbCellera Biologics Inc Прогноза

Ценова цел

By TipRanks

89.49% нагоре

12-месечна прогноза

Среден 6.67 USD 89.49%

Висок 9 USD

Нисък 4 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за AbCellera Biologics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на AbCellera Biologics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.99 / 2.635Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Настроение

By Acuity

308 / 352 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.